Skip to main content
SpringerLink
Log in

Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma a 24-month study

  • Original Article
  • Published:
Annals of Ophthalmology

Abstract

Objective

To compare the long-term efficacy and shortterm escape from effective treatment of 0.005% latanoprost administered once daily vs 0.5% timolol plus 2% dorzolamide twice daily for 24 months to patients with open-angle glaucoma.

Design

Prospective study.

Setting and number of patients

A total of 117 eyes of 61 subjects with open-angle glaucoma were included in this study. The eligible patients were randomized to receive either 0.005% latanoprost once daily or 0.5% timolol and 2% dorzolamide twice daily.

Measurements

The intraocular pressure (IOP) figures were recorded at baseline and at 0.5 1, 3, 6, 9, 12, 15, 18, 21, and 24 months of treatment.

Results

Compared with baseline measurements, both latanoprost and timolol plus dorzolamide treatments caused a significant (p<0.001) reduction of IOP at each visit trroughout the duration of therapy. The IOP was reduced to 17.1±2.4, 16.6±2.2, and 15.9±2.04 with latanoprost and 18.2±2.1, 18.6±2.4, and 18.4±1.9 with timolol plus dorzolamide after 6, 12, and 24 months, respectively. After 24 months, 82% of the patients who initially responsed to treatment were still controlled in the latanoprost group, with a maintained reduction of IOP and no signs of upward drift. However, only 56% of the patients of the timolol plus dorzolamide group were controlled at the end of the study with increase of IOP figures.

Conclusions

Administered once daily, 0.005% latanoprost is more effective than timolol plus dorzolamide twice daily for the long-term treatment of patients with open-angle glaucoma, showing a maintained effect on IOP reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Giuffré G. The effects of Prostaglandin F2α in human eye. Graefe’s Arch Clin Exp Ophthalmol. 1985;222:139–141.

    Article  Google Scholar 

  2. Gabelt BT, Kaufman PL. Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49: 389–402.

    Article  PubMed  CAS  Google Scholar 

  3. Nilsson SPE, Samuelson M, Bill A, et al. Increased uveoscleral out-flow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropyl ester in the cynomolgus monkey. Exp Eye Res. 1989;48:707–716.

    Article  PubMed  CAS  Google Scholar 

  4. Toris CB, Camras CB, Yablosnko ME. Effects of PhXA41, a new prostaglandin F2α analog on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304.

    PubMed  CAS  Google Scholar 

  5. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214–2223.

    PubMed  CAS  Google Scholar 

  6. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. Ophthalmology. 1995;12:743–752.

    Google Scholar 

  7. Watson P, Stjernschantz J. A six month, randomized, double-masked study comparing Latanoprost with Timolol in open angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126–137.

    PubMed  CAS  Google Scholar 

  8. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of Latanoprost and Timolol in primary open-angle glaucoma and ocular hypertension. Arch Ophthalmol. 1996;114: 929–932.

    PubMed  CAS  Google Scholar 

  9. Camras CB, for the United States Latanoprost Study Group. Comparison of Latanoprost and Timolol in patients with ocular hypertension and glaucoma: a six-month, masked muticenter trial in the United States. Ophthalmology. 1996;103:138–147.

    PubMed  CAS  Google Scholar 

  10. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily causes a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with Timolol. Br J Ophthalmol. 1994;76:12–16.

    Google Scholar 

  11. Alm A, Widengard I, Mapea O. Combination of latanoprost with dipivefrin in patients with open angle glaucoma or ocular hypertension. Proceedings of the 27th International Congress of Opthalmology, Toronto, Canada. 1994.

  12. Watson PG, Barnett F, Parker V. The Additive Effects of PhXA41 and Propine in Patients with Primary Open Angle Glaucoma. Oxford, England: 1992.

  13. Rulo AH, Greve EL, Hoyng PF. Additive effect of Latanoprost, a prostaglandin F2a analogue, and Timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899–902.

    PubMed  CAS  Google Scholar 

  14. Rulo AH, Greve EL, Hoyng PFJ. Additive ocular hypotensive effect of Latanoprost and Acetazolamide. Ophthalmology. 1997;104: 1503–1507.

    PubMed  CAS  Google Scholar 

  15. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111:662–665.

    PubMed  Google Scholar 

  16. McClellan K. Topical eye preparations: optimum use. Curr Ther. 1995;36:61–66.

    Google Scholar 

  17. Capino DG, Leibowitz HM. Glaucoma screening, diagnosis, and therapy. Hosp Pract. 1990;25:73–91.

    CAS  Google Scholar 

  18. Coyle D, Drummond M. The economic burden of glaucoma in the UK. The need for a far-sighted policy. PharmacoEconomics. 1995;7: 484–489.

    PubMed  CAS  Google Scholar 

  19. Sherwood MB, Migdal CS, Hitchings RA, et al. Initial treatment of glaucoma; surgery or medications (review). Surv Ophthalmol. 1993; 37:293–305.

    Article  PubMed  CAS  Google Scholar 

  20. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol. 1993;37:270–274.

    PubMed  CAS  Google Scholar 

  21. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhX41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351–1358.

    PubMed  CAS  Google Scholar 

  22. Watson PG, Latanoprost. Two years experience of its use in the United Kingdom. Ophthalmology. 1998;105:83–88.

    Article  Google Scholar 

  23. Hedman K, Alm A. The effect of latanoprost on intraocular pressure up to 24 months’ treatment. Proceedings of the 28th International Congress of Ophthalmology, Amsterdam, Holland, 1998.

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology at “Miguel Servet”, University Hospital, Zaragoza, Spain

    Vicente Polo MD, Jose M. Larrosa MD, Antonio Ferreras MD & Francisco M. Honrubia MD

Authors
  1. Vicente Polo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose M. Larrosa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Ferreras MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francisco M. Honrubia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors do, however, discuss the use of off-label products, which includes unlabeled, unapproved, or investigative devices.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polo, V., Larrosa, J.M., Ferreras, A. et al. Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma a 24-month study. Ann Ophthalmol 37, 33–36 (2005). https://doi.org/10.1385/AO:37:1:033

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/AO:37:1:033

Keywords

Search

Navigation